Design Space Development for Lyophilization Using DOE and Process Modeling - Develop a relevant design space without full factorial DoE. - BioPharm International

ADVERTISEMENT

Design Space Development for Lyophilization Using DOE and Process Modeling
Develop a relevant design space without full factorial DoE.


BioPharm International
Volume 23, Issue 9

DESIGN SPACE DEVELOPMENT: A CASE STUDY

Thermal Characterization and Initial Lyophilization Development


Table 1. Initial/target lyophilization cycle for monoclonal antibody X
The MAb discussed in this case study was formulated in a solution containing a buffer, a sugar lyoprotectant, and a surfactant. To understand the thermal characteristics of this formulation, we performed freeze-drying microscopy experiments.6 The collapse temperature was determined to be –14 C (Figure 3), suggesting that product temperature during primary drying must be maintained well below –14 C.


Figure 4. Process inputs and outputs for lyophilization design space development
During the early process development phase for this molecule, an initial lyophilization cycle (Table 1) was implemented based on prior lyophilization experience with similar products and literature knowledge.7–9 Briefly, the approach consisted of experiments to accomplish primary drying in a reasonable duration while maintaining product temperature well below the collapse temperature.

Risk Assessments for the Lyophilization Unit Operation


Figure 5. Risk ranking and filtering tool (CQA = critical quality attribute)
The process inputs and outputs for lyophilization generally are well known and are shown in Figure 4.7–9 To identify the parameters that must be characterized, we used the risk ranking tool depicted in Figure 5.10 The main and interaction effect scores for each parameter were assigned based on a mechanistic understanding of the lyophilization process and experience with products and equipment. The overall severity score was then used to decide the nature of characterization for the parameter.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here